Lv4
760 积分 2023-01-14 加入
The theory of tumor ecosystem
17天前
已完结
Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis
28天前
已完结
Evolutionary trajectories of small cell lung cancer under therapy
1个月前
已完结
The evolution of lung cancer and impact of subclonal selection in TRACERx
1个月前
已完结
Tolerance in the Age of Immunotherapy
1个月前
已完结
EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
6个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
6个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
6个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
6个月前
已完结
Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC
6个月前
已完结
皖公网安备34019202002308
